Skip to main content
. 2016 Mar 22;7(18):25224–25240. doi: 10.18632/oncotarget.8279

Figure 3. Phospho-ACL is a molecular target of mTORC2.

Figure 3

A. Verification of HER2 and estrogen receptor (ER) status in 6 breast cell lines by immunoblotting. B. Cells were plated in 96-well plates for overnight, treated for 72 h with DMSO, 2 μmol/L WYE-132 or AZD8055, subjected to MTS assays. Net cell growth or death is relative to the initial cell density at initiation of inhibitor treatment. C. Validation of GIPZ-lentivirus shRNA against raptor- (Rap#2, Rap#3) or rictor (Ric#3, Ric#4) in MDA453 cells by immunoblotting. D. and E. Cells of 6 breast lines were infected with Sh-NT, Sh-Rap#2 or Sh-Ric#4, puromycin-resistant cell pools were selected and subjected to immunoblotting (D) and quantitated P-ACL/ACL levels are plotted (E). Statistical analysis: ***, p < 0.001.